GT200900256A - 3-imidazolil-indoles para el tratamiento de las enfermedades proliferativas - Google Patents

3-imidazolil-indoles para el tratamiento de las enfermedades proliferativas

Info

Publication number
GT200900256A
GT200900256A GT200900256A GT200900256A GT200900256A GT 200900256 A GT200900256 A GT 200900256A GT 200900256 A GT200900256 A GT 200900256A GT 200900256 A GT200900256 A GT 200900256A GT 200900256 A GT200900256 A GT 200900256A
Authority
GT
Guatemala
Prior art keywords
imidazolil
indoles
treatment
proliferative diseases
indolilo
Prior art date
Application number
GT200900256A
Other languages
English (en)
Inventor
Boettcher Andreas
Buschmann Nicole
Kallen Joerg
Furet Pascal
Groell Jean-Marc
Hergovich Lisztwan Joanna
Masuya Kelichi
Mayr Lorenz
Vaupel Andrea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38328915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200900256(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200900256A publication Critical patent/GT200900256A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE 3-HETEROCICLIL-INDOLILO CAPACES DE INHIBIR LA INTERACCION ENTRE P53 O VARIANTES DE LA MISMA POR LO QUE AYUDA A CONTROLAR LA INTEGRIDAD CELULAR Y PREVIENE LA PROLIFERACION DE LAS CELULAS PERMANENTEMENTE DAÑADAS.
GT200900256A 2007-03-29 2009-09-28 3-imidazolil-indoles para el tratamiento de las enfermedades proliferativas GT200900256A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07105269 2007-03-29

Publications (1)

Publication Number Publication Date
GT200900256A true GT200900256A (es) 2010-03-15

Family

ID=38328915

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900256A GT200900256A (es) 2007-03-29 2009-09-28 3-imidazolil-indoles para el tratamiento de las enfermedades proliferativas

Country Status (27)

Country Link
US (1) US8053457B2 (es)
EP (1) EP2142535A2 (es)
JP (1) JP2010522723A (es)
KR (1) KR20090122403A (es)
CN (1) CN101679382A (es)
AR (1) AR065860A1 (es)
AU (1) AU2008234954B9 (es)
BR (1) BRPI0810082A2 (es)
CA (1) CA2682483A1 (es)
CL (1) CL2008000899A1 (es)
CR (1) CR11019A (es)
DO (1) DOP2009000229A (es)
EA (1) EA200901212A1 (es)
EC (1) ECSP099660A (es)
GT (1) GT200900256A (es)
IL (1) IL200862A0 (es)
MA (1) MA31260B1 (es)
MX (1) MX2009010413A (es)
NI (1) NI200900177A (es)
PA (1) PA8774001A1 (es)
PE (1) PE20081897A1 (es)
SM (1) SMP200900085B (es)
TN (1) TN2009000388A1 (es)
TW (1) TW200843746A (es)
UY (1) UY30987A1 (es)
WO (1) WO2008119741A2 (es)
ZA (1) ZA200906210B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117401A2 (en) * 2006-04-07 2007-10-18 Janssen Pharmaceutica N.V. Indoles and benzoimidazoles as modulators of the histamine h4 receptor
AR070398A1 (es) * 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
US20100035862A1 (en) * 2008-06-25 2010-02-11 Abbott Laboratories Novel aza-cyclic indole-2-carboxamides and methods of use thereof
MX353900B (es) 2008-11-07 2018-02-01 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
MX2011007598A (es) 2009-01-16 2011-08-08 Daiichi Sankyo Co Ltd Derivados de imidazotiazol que tienen estructura de anillo de prolina.
JP2012102017A (ja) * 2009-03-03 2012-05-31 Astellas Pharma Inc インドール化合物
US20120028990A1 (en) * 2009-04-16 2012-02-02 Msd K.K 3 aryl or heteroaryl-substituted indole derivative
JP2013510860A (ja) 2009-11-12 2013-03-28 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
WO2011106650A2 (en) * 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
JP2013537191A (ja) * 2010-09-08 2013-09-30 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション ｐ５３−Ｍｄｍ２アンタゴニスト
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
AU2011326395B2 (en) 2010-11-12 2016-01-07 Ascenta Licensing Corporation Spiro-oxindole MDM2 antagonists
US20120202794A1 (en) * 2011-01-24 2012-08-09 Pharmasset, Inc. Compounds
SI2684880T1 (en) 2011-03-10 2018-08-31 Daiichi Sankyo Company, Limited DERIVAT DISPIROPYROLIDINE
WO2012135025A2 (en) 2011-03-28 2012-10-04 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
CN102702066A (zh) * 2011-03-28 2012-10-03 苏州百灵威超精细材料有限公司 一种用于合成抗癌和减肥药物中间体6-氯-5-氟吲哚的制备新方法
AU2012253339B2 (en) 2011-05-11 2016-03-31 Sanofi Spiro-oxindole MDM2 antagonists
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
WO2012176123A1 (en) * 2011-06-22 2012-12-27 Novartis Ag 3 - imidazolyl- indoles for the treatment of proliferative diseases
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
RU2014128010A (ru) 2011-12-13 2016-02-10 Бак Инститьют Фо Рисерч Он Эйджин Способы улучшения средств консервативной терапии
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
CA3100140C (en) 2014-01-28 2023-10-24 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
CN106456699B (zh) 2014-05-05 2021-07-02 生物风险投资有限责任公司 作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
JP6503386B2 (ja) 2014-07-03 2019-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体
AU2015292710A1 (en) 2014-07-22 2017-02-16 Bioventures, Llc. Compositions and methods for selectively depleting senescent cells
WO2016101865A1 (en) 2014-12-26 2016-06-30 Dow Global Technologies Llc Organic compounds and electronic device comprising organic layer comprising organic compounds
ES2968789T3 (es) 2015-02-20 2024-05-14 Daiichi Sankyo Co Ltd Procedimiento combinado para el tratamiento del cáncer
WO2016167236A1 (ja) 2015-04-13 2016-10-20 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
EP3310440A1 (de) * 2015-06-22 2018-04-25 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen
JOP20160198B1 (ar) * 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX2018004207A (es) 2015-10-09 2018-07-06 Boehringer Ingelheim Int Nuevos compuestos de espiro[3h-indol-3,2â´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53.
BR112018070549A2 (pt) 2016-04-06 2019-02-12 The Regents Of The University Of Michigan degradantes de proteína mdm2
EP3440082A1 (en) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
US10807977B2 (en) 2016-04-21 2020-10-20 Bioventures, Llc Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof
CN105906610B (zh) * 2016-05-24 2018-10-23 绍兴文理学院 一种3-（4-苯基-1h-咪唑-5-基）-1h-吲哚衍生物及其制备方法和应用
EP3272745B1 (en) * 2016-07-21 2019-06-26 Instytut Farmakologii Polskiej Akademii Nauk Imidazolyl-substituted indole derivatives binding 5-ht7 serotonin receptor and pharmaceutical compositions thereof
KR20190068544A (ko) 2016-10-17 2019-06-18 다이이찌 산쿄 가부시키가이샤 Mdm2 저해제와 dna 메틸트랜스페라아제 저해제의 병용 치료법
EP3544979B1 (en) * 2016-11-28 2021-08-04 F. Hoffmann-La Roche AG Oxadiazolones as transient receptor potential channel inhibitors
MX2019007641A (es) 2016-12-21 2019-09-09 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
CN110461838B (zh) 2017-03-07 2022-05-06 豪夫迈·罗氏有限公司 噁二唑瞬时受体电位通道抑制剂
WO2018185135A1 (en) 2017-04-05 2018-10-11 Boehringer Ingelheim International Gmbh Anticancer combination therapy
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
US11826357B2 (en) * 2017-05-26 2023-11-28 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
PE20240229A1 (es) * 2020-12-22 2024-02-16 Novartis Ag DERIVADOS DE INDOL UTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGAS
WO2022204235A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19948417A1 (de) * 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
JP2002114780A (ja) * 2000-10-11 2002-04-16 Taisho Pharmaceut Co Ltd ４−（３−インドリル）イミダゾール誘導体
CA2752738C (en) 2005-02-22 2014-05-27 The Regents Of The University Of Michigan Small molecule inhibitors of mdm2 and uses thereof
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives

Also Published As

Publication number Publication date
NI200900177A (es) 2010-09-09
UY30987A1 (es) 2008-10-31
WO2008119741A2 (en) 2008-10-09
ZA200906210B (en) 2010-05-26
IL200862A0 (en) 2010-05-17
AU2008234954B2 (en) 2011-10-27
DOP2009000229A (es) 2009-10-31
JP2010522723A (ja) 2010-07-08
PE20081897A1 (es) 2009-02-09
CL2008000899A1 (es) 2009-02-20
CA2682483A1 (en) 2008-10-09
MA31260B1 (fr) 2010-03-01
SMP200900085B (it) 2010-11-12
AU2008234954A1 (en) 2008-10-09
MX2009010413A (es) 2009-10-20
AU2008234954B9 (en) 2012-02-02
US20100125064A1 (en) 2010-05-20
AR065860A1 (es) 2009-07-08
CN101679382A (zh) 2010-03-24
WO2008119741A3 (en) 2008-12-04
EP2142535A2 (en) 2010-01-13
ECSP099660A (es) 2009-10-30
EA200901212A1 (ru) 2010-04-30
TN2009000388A1 (en) 2010-12-31
PA8774001A1 (es) 2008-11-19
BRPI0810082A2 (pt) 2014-10-21
US8053457B2 (en) 2011-11-08
KR20090122403A (ko) 2009-11-27
CR11019A (es) 2009-10-20
TW200843746A (en) 2008-11-16
SMAP200900085A (it) 2010-01-19

Similar Documents

Publication Publication Date Title
GT200900256A (es) 3-imidazolil-indoles para el tratamiento de las enfermedades proliferativas
CU23831B1 (es) Compuestos de pirrolo-pirimidina
CL2008000789A1 (es) Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras.
HN2006037713A (es) Compuestos utiles en terapia
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
HN2011002809A (es) Compuestos de vinil indazolilo
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2008000046A1 (es) Compuestos derivados de 2-(4-piperidin-3-il-fenil)-7-amido-2,7a-dihidro-1h-indazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir el cancer, enfermedades inflamatorias, lesiones por reperfusion, afeccione
CL2008001250S1 (es) Suela para calzado.
BRPI0716435A2 (pt) Compostos para o tratamento de doenças proliferativas
CR10336A (es) Compuestos organicos y sus usos
CL2008001251S1 (es) Suela para calzado.
CL2008002893A1 (es) Compuestos derivados de n-fenil-(piridin-3-il) acetamida sustituidas; composicion farmaceutica; procedimiento de preparacion; y su uso para prevenir o tratar el cancer.
UY32123A (es) Derivados de n - (sustituido) - 4 - (but-2-iniloxi) - benzamida, sus racematos, diastereòmeros, enantiòmeros y las sales de los mismos y aplicaciones
CL2008001247S1 (es) Suela para calzado.
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
CL2008001249S1 (es) Suela para calzado.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CL2008001246S1 (es) Suela para calzado.
GT200500130A (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
GT201000069A (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas
DOP2006000087A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos